ArticleEuropean journal of neurology2025
Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Progress on prognostic assessment methods for mild cognitive impairment].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- Review
- Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeople with Multiple Sclerosis (MS) frequently experience cognitive impairment and neurobehavioral issues including depression and fatigue. We aim to define neuropsychological phenotypes in MS based on cognitive function, depression and fatigue.
methodsIn this cross-sectional study, we collected clinical and neuropsychological data for 600 MS patients. Neuropsychological assessments included Brief International Cognitive Assessment for MS (BICAMS), Beck Depression Inventory (BDI-II) and Modified Fatigue Impact Scale (MFIS). We employed a latent profile analysis (LPA) to unveil latent neuropsychological profiles in MS patients, clustering individuals in unobserved groups, and we compared clinical and MRI features between groups.
resultsLPA identified five neuropsychological phenotypes: Normal neuropsychological phenotype, with normal cognitive and neurobehavioral scores; Isolated cognitive impairment, showing mild reduction in BICAMS scores; Isolated neurobehavioral impairment, showing increased BDI-II and MFIS scores; Mild neuropsychological impairment, showing mildly reduced BICAMS scores, and mildly increased BDI-II and MFIS scores; Severe neuropsychological impairment, showing severely reduced BICAMS scores, and great increase in BDI-II and MFIS scores vs patients with normal neuropsychological phenotype. Relapsing-onset and paediatric-onset patients are more likely in the normal neuropsychological phenotype and isolated cognitive impairment class. Patients with severe neuropsychological impairment showed lower cortical grey matter, thalamic, amygdala, pallidum and putamen volume compared with those with isolated neurobehavioral impairment.
conclusionsWe identified five neuropsychological phenotypes in patients with MS that showed distinct clinical and radiologic features, as from different stages of the disease pathology accrual. Clinical and MRI features may help distinguishing patients requiring closer monitoring of cognitive or neurobehavioral symptoms. DISCLOSURES: Antonio Luca Spiezia, Fabrizia Falco, Federica Lamagna, Martina Eliano, Valerio Nicolella, Antonio Esposito and Cristina Di Monaco have nothing to disclose. Marcello Moccia has received financial support by the MUR PNRR Extended Partnership (MNESYS no. PE00000006, and DHEAL-COM no. PNC-E3-2022-23,683,267); research grants from the ECTRIMS-MAGNIMS, the UK MS Society, and Merck; salary as Assistant Editor of Neurology; and honoraria from Abbvie, Biogen, BMS Celgene, Ipsen, Jansenn, Merck, Novartis, Roche, and Sanofi-Genzyme. Sirio Cocozza has served on scientific advisory board for Amicus Therapeutics, has received speaker honoraria from Sanofi and research grants from Fondazione Italiana Sclerosi Multipla and Telethon. Giuseppe Pontillo was supported by the MAGNIMS/ECTRIMS (2020), ESNR (2021), and ECTRIMS (2022) research fellowship programs. Roberta Lanzillo has received honoraria from Biogen, Merck, Novartis, Roche and Teva. VBM has received research grants from the Italian MS Society, and Roche, and honoraria from Bayer, Biogen, Merck, Mylan, Novartis, Roche, Sanofi- Genzyme and Teva. Vincenzo Brescia Morra has received research grants from Italian MS Federation and Roche; and honoraria from Almirall, Biogen, BMS Celgene, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, and Viatris. Maria Petracca discloses travel/meeting expenses from Novartis, Janssen, Roche and Merck; speaking honoraria from HEALTH&LIFE S.r.l., AIM Education S.r.l., Biogen, Novartis and FARECOMUNICAZIONE E20; honoraria for consulting services and advisory board participation from Biogen; research grants from Baroni Foundation and the Italian Ministry of University and Research. Antonio Carotenuto disclosed research grants from ECTRIMS-MAGNIMS and Almirall, travel/meeting expenses from Novartis, Janssen, Roche and Merck and speaking honoraria from Merk, BMS, Biogen, Novartis, Roche and Almirall.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.